Visual Impairment News and Research RSS Feed - Visual Impairment News and Research

The definition of vision impairment by the Centers for Disease Control and Prevention (CDC) says a visually impaired person’s eyesight cannot be corrected to a “normal level”.
Gene therapy restores visual function in mouse model of LCA1

Gene therapy restores visual function in mouse model of LCA1

Mice lacking the protein retGC1, which is deficient in humans suffering Leber congenital amaurosis-1 (LCA1), a disorder that causes severe visual impairment beginning in infancy, received gene therapy to replace retGC1 and showed fully restored visual function that persisted for at least 6 months. [More]
Researchers receive Bill & Melinda Gates Foundation grant to eliminate neglected tropical diseases

Researchers receive Bill & Melinda Gates Foundation grant to eliminate neglected tropical diseases

Researchers at Washington University School of Medicine in St. Louis have received a $7 million grant from the Bill & Melinda Gates Foundation aimed at eliminating river blindness and elephantiasis, two neglected tropical diseases that annually sicken millions. [More]
Retinal function, structure changes in proliferative diabetic retinopathy revealed

Retinal function, structure changes in proliferative diabetic retinopathy revealed

Patients with proliferative diabetic retinopathy exhibit marked visual dysfunction and structural changes in both the inner and outer retinal layers, research findings indicate. [More]
Benefit and harm of vision screening in preschool-aged children still unclear

Benefit and harm of vision screening in preschool-aged children still unclear

It remains unclear whether a special ophthalmological examination of all children younger than 6 years (and potential follow-up treatments) would reduce the frequency and severity of visual impairment (amblyopia) in the population. An update search conducted for a benefit assessment of the German Institute for Quality and Efficiency in Health Care from 2008 identified no new screening study. [More]
Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO). [More]
CHOP Global Health Center performs first rigorous study of CP outcomes in Africa

CHOP Global Health Center performs first rigorous study of CP outcomes in Africa

Cerebral palsy (CP) is the most common cause of childhood disability in the world, affecting between 1 and 2 infants per thousand. But the neurological condition tends to be understudied, especially in developing countries. [More]
AIDS patients at increased risk of developing intermediate-stage AMD

AIDS patients at increased risk of developing intermediate-stage AMD

Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV, according to results from the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) presented today at the 2015 ARVO Annual Meeting in Denver, CO. [More]
Researchers discover retina protein crucial for vision

Researchers discover retina protein crucial for vision

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the LSU Health New Orleans Neuroscience Center of Excellence, discovered a protein in the retina that is crucial for vision. The paper reports, for the first time, the key molecular mechanisms leading to visual degeneration and blindness. [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson's Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients' vision was deficient at far distances. [More]
RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

RowanSOM researcher awarded NINDS grant to develop stem cell-based therapy for Canavan disease

Paola Leone, PhD, the director of the Cell and Gene Therapy Center and a professor of Cell Biology at the Rowan University School of Osteopathic Medicine, has been awarded a three-year, $477,000 grant from the National Institute of Neurological Disorders and Stroke to develop a stem cell-based therapy for Canavan disease, a rare but devastating neurological disorder in children that typically takes a child's life by age 10. [More]
WHO urges affected countries to increase investment in tackling neglected tropical diseases

WHO urges affected countries to increase investment in tackling neglected tropical diseases

WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030. [More]
Ranibizumab drug reverses diabetes-related blindness

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute. [More]
OIB Program helps older Californians with blindness to live and work independently

OIB Program helps older Californians with blindness to live and work independently

More than ever, older Californians are facing the threat of blindness from age-related eye diseases such as diabetic retinopathy, macular degeneration, cataracts and glaucoma. [More]
Many MEN1 tumour types found in children

Many MEN1 tumour types found in children

Most tumour types reported in adult patients with multiple endocrine neoplasia Type-1 can be found in children with the condition, although rarely before the age of 10 years, shows a large study. [More]
Tackling preventable blindness: a House of Commons reception review

Tackling preventable blindness: a House of Commons reception review

“Macular degeneration is not life threatening, but it is life changing,” these were the words of Michael Valenzia, of the Macular Society at the recent House of Commons Reception held by AMD Alliance International. [More]

Scientists explore how the brain adapts to visual restoration

Recent scientific advances have meant that eyesight can be partially restored to those who previously would have been blind for life. However, scientists at the University of Montreal and the University of Trento have discovered that the rewiring of the senses that occurs in the brains of the long-term blind means that visual restoration may never be complete. [More]

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. [More]
Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. [More]
New study describes revolutionary novel device that has potential to treat eye diseases

New study describes revolutionary novel device that has potential to treat eye diseases

The aging process affects everything from cardiovascular function to memory to sexuality. Most worrisome for many, however, is the potential loss of eyesight due to retinal degeneration. [More]
Advertisement
Advertisement